Zolbetuximab in the treatment of advanced gastric and gastroesophageal junction cancer: a systematic review
IntroductionAdvanced gastric and gastroesophageal junction (G/GEJ) adenocarcinomas are characterized by an aggressive course and a very poor prognosis. Due to the limited benefit of immunotherapy in patients with HER2-negative tumors, new therapeutic t…